Decoy Therapeutics Inc (DCOY)

$5.43 +0.01 (0.09%)
Market Cap 2.88M
Revenue (ttm) 0.00
Net Income (ttm) -12.52M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 8,200
Avg Vol 25,567
Day's Range N/A - N/A
Shares Out 532,000.00
Stochastic %K 18%
Beta 0.37
Analysts Sell
Price Target $30.01

Company Profile

Decoy Therapeutics Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture peptide conjugates targeting various unmet medical needs. The company focuses on building a portfolio o...

Industry: Biotechnology
Sector: Healthcare
Website: decoytx.com
Address:
One Broadway, 14th Floor, Cambridge, United States
Reminderz
Reminderz Apr. 23 at 8:11 PM
$RVPH $DCOY $ADTX $WCT.X spin
0 · Reply
Soupdog420
Soupdog420 Apr. 22 at 3:27 AM
$DCOY letz play a game. Reminds me i lost all shares on last rs with my 2nd accot for 6k
0 · Reply
The_Baba_Yaga
The_Baba_Yaga Apr. 20 at 3:47 PM
$DCOY Really not impressed here shorts. You said sub $5 what are you waiting for?
0 · Reply
struminbanjobio
struminbanjobio Apr. 18 at 3:11 AM
$DCOY interesting collab with the hyperscalers, gates, and quantonium. AI biotech play hasn’t reached mainstream yet. Might see this ran following the AI-Choo Choo train
0 · Reply
Paraboljoker
Paraboljoker Apr. 16 at 6:27 PM
$DCOY Fullportshorted
0 · Reply
The_Baba_Yaga
The_Baba_Yaga Apr. 16 at 6:22 PM
$DCOY Come on shorts lol you gotta try harder
0 · Reply
The_Baba_Yaga
The_Baba_Yaga Apr. 16 at 6:17 PM
$DCOY Anyone even here?
0 · Reply
MySwingAmari
MySwingAmari Apr. 15 at 6:49 PM
$DCOY
0 · Reply
focafoca99
focafoca99 Apr. 9 at 8:41 PM
$DCOY is framing 2026 as a highly catalytic period to move its D-MAV antiviral platform toward the clinic.
0 · Reply
VirtualInvestor
VirtualInvestor Apr. 9 at 4:49 PM
$DCOY 🔔 Going Live Today at 4 PM ET! Decoy Therapeutics will be on the air at 4 PM ET for a #VirtualInvestor Closing Bell segment with CEO Rick Pierce. Access the Event Here: https://bit.ly/4dyOsQK $DCOY #Flu #RSV #COVID #AIDrugDiscovery
1 · Reply
Latest News on DCOY
Decoy Therapeutics Transcript: Status update

Apr 9, 2026, 4:00 PM EDT - 16 days ago

Decoy Therapeutics Transcript: Status update

Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline

Apr 9, 2026, 8:36 AM EDT - 16 days ago

Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline

Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026

Apr 6, 2026, 9:15 AM EDT - 19 days ago

Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026

Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apr 2, 2026, 9:00 AM EDT - 23 days ago

Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform

Mar 11, 2026, 8:30 AM EDT - 6 weeks ago

Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform

Decoy Therapeutics Announces 1-for-12 Reverse Stock Split

Mar 5, 2026, 8:30 AM EST - 7 weeks ago

Decoy Therapeutics Announces 1-for-12 Reverse Stock Split

Decoy Therapeutics Joins Webull Corporate Connect Service Platform

Feb 11, 2026, 9:00 AM EST - 2 months ago

Decoy Therapeutics Joins Webull Corporate Connect Service Platform

Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Feb 5, 2026, 9:15 AM EST - 2 months ago

Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement

Feb 4, 2026, 9:02 AM EST - 2 months ago

Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement

Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform

Jan 13, 2026, 8:15 AM EST - 3 months ago

Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform

Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics

Jan 7, 2026, 8:45 AM EST - 3 months ago

Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics

Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting

Dec 19, 2025, 11:12 AM EST - 4 months ago

Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting

Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform

Dec 18, 2025, 7:50 AM EST - 4 months ago

Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform

Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study

Dec 1, 2025, 8:00 AM EST - 5 months ago

Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study

Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”

Nov 19, 2025, 2:42 PM EST - 5 months ago

Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”

Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger

Nov 13, 2025, 8:45 AM EST - 5 months ago

Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger

Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering

Nov 11, 2025, 9:18 AM EST - 5 months ago

Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering

Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements

Oct 13, 2025, 8:45 AM EDT - 6 months ago

Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sep 9, 2025, 8:00 AM EDT - 8 months ago

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split

Aug 14, 2025, 8:30 AM EDT - 9 months ago

Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split

Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard

Jul 14, 2025, 8:30 AM EDT - 10 months ago

Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard

Salarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies

Jul 9, 2025, 8:30 AM EDT - 10 months ago

Salarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board

Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update

Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers

Feb 3, 2025, 8:00 AM EST - 1 year ago

Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers

Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge

Jan 13, 2025, 2:12 PM EST - 1 year ago

Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge

Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Jun 12, 2024, 8:00 AM EDT - 2 years ago

Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 22, 2024, 4:05 PM EDT - 2 years ago

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment

Jan 3, 2024, 8:30 AM EST - 2 years ago

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment

Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

Nov 7, 2023, 8:30 AM EST - 2 years ago

Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update

Aug 10, 2023, 4:05 PM EDT - 2 years ago

Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update

Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients

Jul 11, 2023, 8:30 AM EDT - 3 years ago

Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients

Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress

Jun 12, 2023, 8:00 AM EDT - 3 years ago

Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress

Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

May 16, 2023, 4:05 PM EDT - 3 years ago

Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

May 12, 2023, 8:00 AM EDT - 3 years ago

Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update

May 11, 2023, 8:00 AM EDT - 3 years ago

Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update

Salarius Pharmaceuticals stock soars premarket after FDA lifts partial clinical hold on trial of treatment for rare form of cancer that starts in childhood

May 9, 2023, 8:17 AM EDT - 3 years ago

Salarius Pharmaceuticals stock soars premarket after FDA lifts partial clinical hold on trial of treatment for rare form of cancer that starts in childhood

FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals' Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma

May 9, 2023, 8:00 AM EDT - 3 years ago

FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals' Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma

Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164

May 1, 2023, 8:30 AM EDT - 3 years ago

Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164

Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting

Apr 20, 2023, 8:30 AM EDT - 3 years ago

Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting

Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference

Apr 4, 2023, 4:02 PM EDT - 3 years ago

Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Mar 27, 2023, 8:30 AM EDT - 3 years ago

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting

Mar 15, 2023, 11:00 AM EDT - 3 years ago

Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting

Salarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of Texas

Feb 16, 2023, 8:30 AM EST - 3 years ago

Salarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of Texas

Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Jan 27, 2023, 8:30 AM EST - 3 years ago

Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Jan 19, 2023, 8:30 AM EST - 3 years ago

Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Investigators Present Clinical Data on Salarius Pharmaceuticals' Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting

Dec 13, 2022, 8:01 AM EST - 3 years ago

Investigators Present Clinical Data on Salarius Pharmaceuticals' Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting

Salarius Pharmaceuticals Presents SP-3164 Data Demonstrating Activity in Preclinical Lymphoma Models at the American Society of Hematology Annual Meeting

Dec 13, 2022, 8:00 AM EST - 3 years ago

Salarius Pharmaceuticals Presents SP-3164 Data Demonstrating Activity in Preclinical Lymphoma Models at the American Society of Hematology Annual Meeting

Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Dec 1, 2022, 8:00 AM EST - 3 years ago

Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Nov 10, 2022, 8:30 AM EST - 3 years ago

Salarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Decoy Therapeutics Earnings Call Transcript: Q2 2022

Aug 8, 2022, 9:00 AM EDT - 4 years ago

Decoy Therapeutics Earnings Call Transcript: Q2 2022

Reminderz
Reminderz Apr. 23 at 8:11 PM
$RVPH $DCOY $ADTX $WCT.X spin
0 · Reply
Soupdog420
Soupdog420 Apr. 22 at 3:27 AM
$DCOY letz play a game. Reminds me i lost all shares on last rs with my 2nd accot for 6k
0 · Reply
The_Baba_Yaga
The_Baba_Yaga Apr. 20 at 3:47 PM
$DCOY Really not impressed here shorts. You said sub $5 what are you waiting for?
0 · Reply
struminbanjobio
struminbanjobio Apr. 18 at 3:11 AM
$DCOY interesting collab with the hyperscalers, gates, and quantonium. AI biotech play hasn’t reached mainstream yet. Might see this ran following the AI-Choo Choo train
0 · Reply
Paraboljoker
Paraboljoker Apr. 16 at 6:27 PM
$DCOY Fullportshorted
0 · Reply
The_Baba_Yaga
The_Baba_Yaga Apr. 16 at 6:22 PM
$DCOY Come on shorts lol you gotta try harder
0 · Reply
The_Baba_Yaga
The_Baba_Yaga Apr. 16 at 6:17 PM
$DCOY Anyone even here?
0 · Reply
MySwingAmari
MySwingAmari Apr. 15 at 6:49 PM
$DCOY
0 · Reply
focafoca99
focafoca99 Apr. 9 at 8:41 PM
$DCOY is framing 2026 as a highly catalytic period to move its D-MAV antiviral platform toward the clinic.
0 · Reply
VirtualInvestor
VirtualInvestor Apr. 9 at 4:49 PM
$DCOY 🔔 Going Live Today at 4 PM ET! Decoy Therapeutics will be on the air at 4 PM ET for a #VirtualInvestor Closing Bell segment with CEO Rick Pierce. Access the Event Here: https://bit.ly/4dyOsQK $DCOY #Flu #RSV #COVID #AIDrugDiscovery
1 · Reply
Elainas
Elainas Apr. 8 at 7:56 PM
$DCOY
0 · Reply
VirtualInvestor
VirtualInvestor Apr. 8 at 3:41 PM
$DCOY Tomorrow at 4 PM ET, don't miss Decoy Therapeutics in the #VirtualInvestor Closing Bell Series. Tune in to hear directly from CEO Rick Pierce and get your questions answered live! Register here: https://bit.ly/4dyOsQK
0 · Reply
DeadSunxx
DeadSunxx Apr. 7 at 9:10 PM
$DCOY heated took a very minor l on this earlier
0 · Reply
Shortski
Shortski Apr. 7 at 9:09 PM
$DCOY going below $5 tonight
1 · Reply
SuperGreenToday
SuperGreenToday Apr. 7 at 4:15 PM
$DCOY
0 · Reply
focafoca99
focafoca99 Apr. 6 at 6:41 PM
$DCOY is just promoting an investor event, with management scheduled for a virtual closing-bell presentation on the 2026 outlook.
0 · Reply
NetNinja
NetNinja Apr. 3 at 6:15 AM
$DCOY This is called the slow spiral of death. I'll give this another month before it's under $1 again.
0 · Reply
focafoca99
focafoca99 Apr. 2 at 7:56 PM
$DCOY has regained compliance with Nasdaq's minimum bid price rule, removing one near-term listing overhang.
0 · Reply
gopiathukuri
gopiathukuri Apr. 2 at 5:03 PM
$DCOY i think we need more volume. Hoping to see some movement since they gained nasdaq compliance officially as of today.
0 · Reply
gopiathukuri
gopiathukuri Apr. 2 at 5:02 PM
$DCOY this is crazy it keeps going down 5-6% with this low volume. Even an order of 140 shares is bringing this down by 5%.
0 · Reply
STACKD0E
STACKD0E Apr. 2 at 1:35 PM
$CODX $DCOY ✨
0 · Reply
RichieGreen
RichieGreen Apr. 1 at 7:12 PM
$DCOY who is selling to get it down that excessive percentage without volume?
0 · Reply